In this Application Note we discuss:
More about this Application Note
CAR-T cell-based immunotherapies have had remarkable success in recent years, but challenges remain.
Reengineered T cells are living products whose behavior has been difficult to characterize and predict with existing technologies. Once they are re-infused into the patient, they may result in life-threatening immunotoxicity such as cytokine release syndrome (CRS) and neurologic toxicity.
Download this App Note to learn how IsoPlexis’ Polyfunctional Strength Index (PSI™) can be utilized to address these challenges, in particular, to provide metrics that uniquely relate the cell product response to in vivo preclinical and clinical outcome measures.